ÂÜÀòÂÒÂ×

Samuel Cohen has a wealth of work experience, beginning with two Summer Analyst roles at Goldman Sachs in 2007 and 2008. Samuel then went on to work as a Consultant at The Boston Consulting Group in 2013, while also taking on a Research Fellow role at the University of Cambridge. In 2015, they became a Director of Scientific Investments at Malin Corporation plc, where they were a Board Observer of Poseida Therapeutics. In 2016, they Co-Founded and became Board Member of Wren Therapeutics Ltd, where they also served as Chief Executive Officer. In 2018, they took on an Entrepreneur-In-Residence role at the University of Cambridge, and in 2020 they Co-Founded and became a Board Member of Transition Bio, Inc.

Samuel Cohen attended the University of Cambridge from 2005 to 2009, obtaining a BA in Natural Sciences in 2008, followed by an MSci in Natural Sciences in 2009. In 2012, they received a Doctor of Philosophy in Biophysical Chemistry from the University of Cambridge. During this time, they were also a Kennedy Scholar and Visiting Fellow at Harvard University from 2011 to 2012.